Skip to main content
EnnoDC  I  News & Events

Live

I  Use the filters to find our latest press releases, upcoming events and video interviews
EnnoDC presents positive Phase I data at CROI 2025, demonstrating long-lasting immunity induced by Antibody Mediated Vaccines (AMVs)FeaturedInfectious Diseases

EnnoDC presents positive Phase I data at CROI 2025, demonstrating long-lasting immunity induced by Antibody Mediated Vaccines (AMVs)

March 9, 2025
EnnoDC presents preliminary data for immunotherapy candidate CD40.HVac in HPV+ oropharyngeal cancer at ESMO IO 2024FeaturedOncology

EnnoDC presents preliminary data for immunotherapy candidate CD40.HVac in HPV+ oropharyngeal cancer at ESMO IO 2024

December 9, 2024
ICR Consilium Healthcare ConferenceCorporateFeatured

ICR Consilium Healthcare Conference

November 18, 2024
42nd Annual J.P. Morgan Healthcare ConferenceCorporate

42nd Annual J.P. Morgan Healthcare Conference

November 8, 2024
BIO Europe Partnering EventCorporate

BIO Europe Partnering Event

November 4, 2024
ESMO Immuno-Oncology Congress 2024Oncology

ESMO Immuno-Oncology Congress 2024

October 18, 2024
Results from a Phase I clinical trial of a dendritic cell targeting prophylactic HIV vaccine published in the Journal eClinical MedicineInfectious Diseases

Results from a Phase I clinical trial of a dendritic cell targeting prophylactic HIV vaccine published in the Journal eClinical Medicine

October 2, 2024
EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategyCorporate

EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategy

September 26, 2024
LinKinVax and Gustave Roussy announced first patient dosed in Phase I/IIa clinical study on HPV.DCVax in HPV-positive oropharyngeal cancerOncology

LinKinVax and Gustave Roussy announced first patient dosed in Phase I/IIa clinical study on HPV.DCVax in HPV-positive oropharyngeal cancer

September 18, 2023
LinKinVax completes first batch production of “pancov”, its next generation multi-variant vaccine against covid and other coronavirusesInfectious Diseases

LinKinVax completes first batch production of “pancov”, its next generation multi-variant vaccine against covid and other coronaviruses

July 20, 2023
LinKinVax welcomes interim results of the ANRS VRI06 Phase I trial evaluating a novel HIV vaccineInfectious Diseases

LinKinVax welcomes interim results of the ANRS VRI06 Phase I trial evaluating a novel HIV vaccine

February 22, 2023
LinKinVax and Gustave Roussy Collaborate on a Phase I/IIa HPV.DCVax Clinical Trial for the Treatment of Patients with HPV-Positive Oropharyngeal CancerOncology

LinKinVax and Gustave Roussy Collaborate on a Phase I/IIa HPV.DCVax Clinical Trial for the Treatment of Patients with HPV-Positive Oropharyngeal Cancer

January 19, 2023
LinKinvax just completed a new round of financing, initiated in 2022, for a total of €7,3 M, supporting its next series A round up to € 50 MCorporate

LinKinvax just completed a new round of financing, initiated in 2022, for a total of €7,3 M, supporting its next series A round up to € 50 M

January 9, 2023
LinKinVax raises €4.350 Million in Funding to accelerate the development of its innovative vaccine platformCorporate

LinKinVax raises €4.350 Million in Funding to accelerate the development of its innovative vaccine platform

February 10, 2022
LinKinVax and Inserm Transfert enter into an exclusive worldwide licensing agreement covering use of an innovative vaccine platformCorporate

LinKinVax and Inserm Transfert enter into an exclusive worldwide licensing agreement covering use of an innovative vaccine platform

February 3, 2022
LinKinVax-Labex VRI consortium secures 31M€ in public funding to develop a booster vaccine against COVID-19Corporate

LinKinVax-Labex VRI consortium secures 31M€ in public funding to develop a booster vaccine against COVID-19

May 26, 2021
ICR Consilium Healthcare ConferenceCorporateFeatured

ICR Consilium Healthcare Conference

November 18, 2024
42nd Annual J.P. Morgan Healthcare ConferenceCorporate

42nd Annual J.P. Morgan Healthcare Conference

November 8, 2024
BIO Europe Partnering EventCorporate

BIO Europe Partnering Event

November 4, 2024
EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategyCorporate

EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategy

September 26, 2024
LinKinvax just completed a new round of financing, initiated in 2022, for a total of €7,3 M, supporting its next series A round up to € 50 MCorporate

LinKinvax just completed a new round of financing, initiated in 2022, for a total of €7,3 M, supporting its next series A round up to € 50 M

January 9, 2023
LinKinVax raises €4.350 Million in Funding to accelerate the development of its innovative vaccine platformCorporate

LinKinVax raises €4.350 Million in Funding to accelerate the development of its innovative vaccine platform

February 10, 2022
LinKinVax and Inserm Transfert enter into an exclusive worldwide licensing agreement covering use of an innovative vaccine platformCorporate

LinKinVax and Inserm Transfert enter into an exclusive worldwide licensing agreement covering use of an innovative vaccine platform

February 3, 2022
LinKinVax-Labex VRI consortium secures 31M€ in public funding to develop a booster vaccine against COVID-19Corporate

LinKinVax-Labex VRI consortium secures 31M€ in public funding to develop a booster vaccine against COVID-19

May 26, 2021
EnnoDC  I  France
PariSanté Campus
10, rue d’Oradour-sur-Glane
75015 Paris
France
EnnoDC  I  US
255 Main Street, STE 200
Cambridge, MA 02142-1029
United States
© EnnoDC 2024